Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Acquires Profitable Growth Dermatology Products
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3018)
•••
Post by Betteryear2on Jul 29, 2024 2:24pm
209 Views
Post# 36153001

Acquires Profitable Growth Dermatology Products

Acquires Profitable Growth Dermatology ProductsCraig Mull, Interim CEO commented: "Our acquisition of the Natroba™ products and the ParaPro commercial infrastructure is a pivotal step in our strategy to establish a leading dermatology platform featuring unique, innovative products. ParaPRO has a demonstrated strong sales, gross margin and earnings profile, making it a natural fit with our existing business. With this acquisition we have not only doubled the current sales and earnings of Cipher's business today but we have greatly enhanced the capabilities of our dermatology focused strategy.

Cipher Pharmaceuticals Acquires Profitable Growth Dermatology Products from ParaPRO for US$89.5 Million (newswire.ca)


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities